SAN DIEGO – Mirador Therapeutics, Inc., a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I), today announced the appointment of Gregg Gilbert as chief financial officer. Mr. Gilbert brings more than 25 years of leadership experience in biopharma equity research analysis and investment banking to the role. “Since launching earlier this year with over $400 million in … Continue reading Mirador Therapeutics Appoints Gregg Gilbert as Chief Financial Officer

IRVINE, Calif. – BioDuro-Sundia, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the appointment of Dr. Armin Spura as its new Chief Executive Officer. Dr. Spura brings over two decades of experience in the life sciences and biotechnology sectors, with a proven track record of driving growth and innovation across global markets. With our CRDMO platform encompassing chemistry, biology, DMPK, … Continue reading BioDuro-Sundia Appoints Dr. Armin Spura as New Chief Executive Officer

Funding will Advance Cellino’s Advanced Biomanufacturing Technology for Personalized Regenerative Medicines CAMBRIDGE, Mass. – Cellino Biotech, Inc. today announced that the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, has awarded it up to $25 million in funding to develop an ultra-scalable, autonomous, cassette-based advanced biomanufacturing technology for personalized regenerative medicines. Cellino’s NEBULA (NExt-generation Biomanufacturing ULtra-scalable … Continue reading Cellino Awarded $25M in Funding from the Advanced Research Projects Agency for Health (ARPA-H)

Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ — Azenta, Inc. (Nasdaq: AZTA) (“Azenta” or “the Company”), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades … Continue reading AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO